SCHEMBL4956879

SCHEMBL4956879

Nc1ccccc1C(=O)Nc1ccccc1NC(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.69
RAB9A P51151 4/20 0.69
KDM4E B2RXH2 4/20 0.69
HSD17B10 Q99714 2/20 0.69
CASP3 P42574 1/20 0.69
SENP8 Q96LD8 1/20 0.69
SENP7 Q9BQF6 1/20 0.69
SENP6 Q9GZR1 1/20 0.69
HDAC1 Q13547 3/20 0.57
ALDH1A1 P00352 4/20 0.56
MAPK1 P28482 3/20 0.56
HDAC3 O15379 2/20 0.56
HDAC2 Q92769 2/20 0.56
PYGL P06737 1/20 0.53
FADS1 O60427 3/20 0.53
PTGS1 P23219 2/20 0.50
NCOR2 Q9Y618 1/20 0.50
GAA P10253 3/20 0.49
P2RX1 P51575 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11743614 0.93 NPC1 (0.72) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL392793 0.87 NPC1 (0.70) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL1702919 0.86 NPC1 (0.74) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL30489855 0.86 NPC1 (0.74) NPC1RAB9AKDM4EHSD17B10CASP3
Hydrochloric Acid SCHEMBL11743643 0.85 NPC1 (0.68) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL7717671 0.84 NPC1 (0.72) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL7722705 0.84 NPC1 (0.72) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL31462147 0.84 NPC1 (0.68) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL31606761 0.84 NPC1 (0.68) NPC1RAB9AKDM4EHSD17B10CASP3
SCHEMBL4642645 0.84 NPC1 (0.68) NPC1RAB9AKDM4EHSD17B10CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008094909-A2 QUINAZOLINONE AND FUSED PYRIMIDINONE COMPOUNDS AND THEIR USE IN TREATING SODIUM CHANNEL-MEDIATED DISEASES OR CONDITIONS XENON PHARMACEUTICALS INC. (CA) 2008-08-07 WO disclosed